

CURRICULUM VITAE

Stefan Woehrer, MD, PhD, FACP



February 7th, 2024

PERSONAL INFORMATION

Date of Birth: 31.03.1977
Place of Birth: Vienna, Austria Austria

Work Address: Schwarzottstraße 2a
2620 Neunkirchen
Austria
+43 21012 602

CURRENT POSITIONS

- CEO of Permedio – Center for Personalized Medicine (since 10/2015):
Internal Medicine, Sports Medicine, Oncology, Hematology
- Founder and CEO of Permedio International GmbH (since 03/2020)
Company for the development, sales, and distribution of medical products

PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS

- Medical Officer (Oncology & Hematology), PSI CRO 12/2019-12/2020
- Associate Professor at the University of Applied Sciences Wiener Neustadt (10/2016 - 12/2019)
- Attending physician at the General Hospital Baden (community hospital in Baden) (01/2018 – 09/2019)
- Attending Physician at the General Hospital Wr. Neustadt, Comprehensive Cancer Center (9/2013 – 5/2017)
- Principal Investigator for Experimental Stemcell Research at the Anna Spiegel Building from (8/2012 – 12/2016)
- Program director of the Clinical and Experimental Stem Cell Research Unit at the Medical University of Vienna (01/2012 – 08/2013)
- Associate Professor at the Medical University of Vienna (01/2012 – 08/2013)
- Research Fellow with Prof. Connie Eaves at the Terry Fox Laboratory at the British Columbia Cancer Research Center in Vancouver, Canada (05/2007 – 05/2011)
- Leukemia/BMT Fellow at the Vancouver General Hospital, Canada (06/2009-05/2011)
- Fellow in internal medicine, hematology and oncology at the Medical University of Vienna (06/2002 – 05/2007 + 06/2011 – 01/2012)
- Internal Consultant with Novartis Pharma (03/2002 – 06/2002)

EDUCATION/POST GRADUATE TRAINING

- University/Medical School: Medical University of Vienna, Austria: MD (1997-2002) -> **Medical Doctor (MD)**
- **Residency** in Internal Medicine and **Fellowship** in Hematology&Oncology: Medical University of Vienna, Austria: (06/2002-05/2007 and 06/2011-01/2012)

- **Fellowship** (Leukemai/BMT Service): British Columbia Cancer Center, Vancouver, Canada Leukemia/BMT Service: (06/2009-05/2011)
- **Doctor of Philosophy (PhD)**, Malignant Diseases Program: Medical University of Vienna and British Columbia Cancer Research Center (05/2007-02/2016) -> **PhD**
- **Certification Program**: Program for Medical Educators at the Medical University of Vienna: (8/2011-8/2013)
- **Certification Program**: Principal Investigator of Clinical Studies at the Vienna School of Clinical Research: (3/2005-5/2007)
 - Introduction to Good Clinical Practice
 - Introduction to Clinical Research
 - Introduction to Biostatistics
 - Advanced Biostatistics
 - Introduction to Clinical Epidemiology
 - Project Management in Clinical Research
 - Publication Workshop: How to Write a Biomedical Research Paper
 - Publication Masterclass
 - Ethical Aspects in Clinical Research
 - Scientific Aspects of Clinical Trials - Protocol Development Workshop
- **Certification Program**: Human Genetics, Austrian College of Physicians (10/2015 - 3/2016)
- **Certification Program**: Sports Medicine, Austrian College of Physicians (10/2022- 10/2023)

MEDICAL LICENSURE

- Austrian Medical Association, Active, # 49719-96

BOARD CERTIFICATION

- Internal Medicine 02/2012
- Hematology&Oncology 03/2013

MILITARY SERVICES

- Mandatory Military Service: 10/96-10/97, Infantry, Wr. Neustadt, rank: Gefreiter

TEACHING ACTIVITIES–HOSPITAL OR OFFICE-BASED

- Associate Professor at the University of Applied Sciences in Wr. Neustadt: Healthcare and Nursing: Anatomy, Physiology, Biology, Pathology, Diagnosis and Therapy (11/2016-12/2019)
- Lecturer and Examiner at the Medical University of Vienna: Clinically Applied Stem Cell Therapy since (11/2013-11/2014)
- Tutor and Examiner at the Medical University of Vienna: Physical Examination (11/2011 – 11/2013)
- Tutor and Examiner at the Medical University of Vienna: Physician/Patient Relationship and History Taking (06/2004 06/2007)
- Bedside Teaching for Medical Students in Internal Medicine at the General Hospital in Wr. Neustadt: (09/2013 – 5/2017)
- Bedside Teaching for Residents in Internal Medicine at the General Hospital in Wr. Neustadt: (09/2013 – 5/2017)
- Bedside and Office based Teaching for Fellows in Hematology and Oncology at the General Hospital in Wr. Neustadt (09/2013 – 5/2017)

HOSPITAL/UNIVERSITY COMMITTEE APPOINTMENTS

- Associate Professor in Internal Medicine at the Medical University of Vienna (01/2012 – 08/2013)
- Program Director for Clinical and Experimental Stem Cell Research at the Medical University of Vienna (01/2012 – 08/2013)
- Leader of the Fellow Exchange program at the Medical University of Vienna (2004-2006)

HONORS AND AWARDS

- DDr. Karl Fellingner Cancer Research Award 2007
- Erwin-Schroedinger Fellowship 2007
- ASH Travel Award 2010
- Basic Research Award for the best basic research abstract EBMT 2012
- EHA Travel Grant 2012
- FWF stand-alone grant 2013
- rizup Genius Award 2018

- AWS Digital Grant Award 2019

PROFESSIONAL AND SOCIETY MEMBERSHIPS

- American College of Physicians (ACP) 2009 - ongoing
- Austrian Society of Hematology and Oncology (OEGHO) 2013 - ongoing
- American Society of Hematology (ASH) 2011 - 2013
- European Society of Hematology (EHA) 2011 - 2013
- European Group for Blood and Marrow Transplantation (EBMT) 2011 - 2013

EDITORIAL ACTIVITIES

- Reviewer for: Lancet, Lancet Oncology, Blood, Journal of Clinical Oncology, Annals of Oncology, British Journal of Hematology,

BIBLIOGRAPHY

Original Papers:

1: **Wohrer S**, Knapp D, Copley M, Benz C, Kent D, Rowe K, Babovic S, Mader H, Oostendorp R, Eaves C. Distinct Niche Factors Can Control Hematopoietic Stem Cell Survival, Proliferation and Self-Renewal. Cell Reports 2014 accepted IF=estimated at 15,000

2: **Wohrer S**, Kiesewetter B, Fischbach J, Müllauer L, Troch M, Lukas J, Mayerhoefer MA, and Raderer M. Retrospective Comparison of the Effectiveness of Various Treatment Modalities of Extragastric MALT Lymphoma: A single center analysis. Annals of Hematology 2014 in press. IF=2,866

3: Copley MR, Babovic S, Benz C, Knapp DJ, Beer PA, Kent DG, **Wohrer S**, Treloar DQ, Day C, Rowe K, Mader H, Kuchenbauer F, Humphries RK, Eaves CJ. The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nat Cell Biol. 2013 Aug;15(8):916-25. doi: 10.1038/ncb2783. Epub 2013 Jun 30. PubMed PMID: 23811688. IF=20,761

4: Benz C, Copley MR, Kent DG, **Wohrer S**, Cortes A, Aghaeepour N, Ma E, Mader H, Rowe K, Day C, Treloar D, Brinkman RR, Eaves CJ. Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs. Cell Stem Cell. 2012 Mar 2;10(3):273-83. doi: 10.1016/j.stem.2012.02.007. PubMed PMID: 22385655. IF=27,36

5: Lecault V, Vaninsberghe M, Sekulovic S, Knapp DJ, **Wohrer S**, Bowden W, Viel F, McLaughlin T, Jarandehi A, Miller M, Falconnet D, White AK, Kent DG, Copley MR, Taghipour F, Eaves CJ, Humphries RK, Piret JM, Hansen CL. High-throughput analysis of single hematopoietic stem cell proliferation in microfluidic cell culture arrays. Nat Methods. 2011 May 22;8(7):581-6. doi: 10.1038/nmeth.1614. PubMed PMID: 21602799. IF=20,711

6: Fink D, **Wohrer S**, Pfeffer M, Tombe T, Ong CJ, Sorensen PH. Ubiquitous expression of the monomeric red fluorescent protein mCherry in transgenic mice. Genesis. 2010 Dec;48(12):723-9. doi: 10.1002/dvg.20677. Epub 2010 Nov 19. PubMed PMID: 20853428. IF=2,395

7: Boehm A, Walcherberger B, Sperr WR, **Woehrer S**, Dieckmann K, Rosenmayr AE, Fischer G, Worel N, Mitterbauer G, Schwarzinger I, Mitterbauer M, Haas OA, Lechner K, Hinterberger W, Valent P, Greinix HT, Rabitsch W, Kalhs P. Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. *Biol Blood Marrow Transplant*. 2011 Jan;17(1):133-40. Epub 2010 Jul 1. PubMed PMID: 20601032. IF=3,275

8: Troch M, **Woehrer S**, Raderer M. Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma. *Anticancer Res*. 2010 Feb;30(2):635-9. PubMed PMID: 20332482. IF=1,656

9: Kent DG, Copley MR, Benz C, **Woehrer S**, Dykstra BJ, Ma E, Cheyne J, Zhao Y, Bowie MB, Zhao Y, Gasparetto M, Delaney A, Smith C, Marra M, Eaves CJ. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. *Blood*. 2009 Jun 18;113(25):6342-50. Epub 2009 Apr 17. PubMed PMID: 19377048. IF=10,558

10: Troch M, **Woehrer S**, Streubel B, Weissel M, Hoffmann M, Müllauer L, Chott A, Raderer M. Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. *Ann Oncol*. 2008 Jul;19(7):1336-9. Epub 2008 Mar 11. PubMed PMID: 18334510. IF=6,452

11: **Woehrer S**, Rabitsch W, Shehata M, Kondo R, Esterbauer H, Streubel B, Sillaber C, Raderer M, Jaeger U, Zielinski C, Valent P. Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph⁺ acute leukaemia are not related to the leukaemic clone. *Anticancer Res*. 2007 Nov-Dec;27(6B):3837-41. PubMed PMID: 18225540. IF=1,656

12: Gruenberger B, **Woehrer S**, Troch M, Hauff W, Lukas J, Streubel B, Muellauer L, Chott A, Raderer M. Assessment of the role of hepatitis C, Helicobacter pylori and autoimmunity in MALT lymphoma of the ocular adnexa in 45 Austrian patients. *Acta Oncol*. 2008;47(3):355-9. PubMed PMID: 17957504. IF=3,137

13: **Woehrer S**, Troch M, Streubel B, Hoffmann M, Müllauer L, Chott A, Raderer M. Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. *Ann Oncol*. 2007 Dec;18(12):2020-4. Epub 2007 Sep 4. PubMed PMID: 17785766. IF=6,452

14: **Wohrer S**, Troch M, Streubel B, Zwerina J, Skrabs C, Formanek M, Hauff W, Hoffmann M, Müllauer L, Chott A, Raderer M. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. *Leukemia*. 2007 Aug;21(8):1812-8. Epub 2007 Jun 7. PubMed PMID: 17554381. IF=8,966

15: Raderer M, **Wohrer S**, Streubel B, Drach J, Jager U, Turetschek K, Troch M, Puspok A, Zielinski CC, Chott A. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. *Oncology*. 2006;70(6):411-7. Epub 2007 Jan 12. PubMed PMID: 17220639. IF=2,538

16: **Wohrer S**, Troch M, Zwerina J, Schett G, Skrabs C, Gaiger A, Jaeger U, Zielinski CC, Raderer M. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. *Ann Oncol*. 2007 Apr;18(4):647-51. Epub 2007 Jan 11. PubMed PMID: 17218490. IF=6,452

17: Streubel B, Huber D, **Wohrer S**, Chott A, Raderer M. Reverse transcription-PCR for t(11;18)(q21;q21) staging and monitoring in mucosa-associated lymphoid tissue lymphoma. *Clin Cancer Res*. 2006 Oct 15;12(20 Pt 1):6023-8. PubMed PMID: 17062676. IF=7,338

18: Hoffmann M, **Wohrer S**, Becherer A, Chott A, Streubel B, Kletter K, Raderer M. 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. *Ann Oncol*. 2006 Dec;17(12):1761-5. Epub 2006 Sep 15. PubMed PMID: 16980600. IF=6,452

19: Bartsch R, **Wohrer S**, Raderer M, Hejna M. Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. *Anticancer Res*. 2006 Jul-Aug;26(4B):3187-90. PubMed PMID: 16886655. IF=1,656

20: Raderer M, **Wohrer S**, Streubel B, Troch M, Turetschek K, Jäger U, Skrabs C, Gaiger A, Drach J, Puspok A, Formanek M, Hoffmann M, Hauff W, Chott A. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. *J Clin Oncol*. 2006 Jul 1;24(19):3136-41. Epub 2006 Jun 12. PubMed PMID: 16769982. IF=18,970

- 21: Jäger G, Neumeister P, Quehenberger F, **Wohrer S**, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. *Ann Oncol*. 2006 Nov;17(11):1722-3. Epub 2006 Jun 9. PubMed PMID: 16766585. IF=6,452
- 22: Grunberger B, **Wohrer S**, Streubel B, Formanek M, Petkov V, Puespoek A, Haefner M, Hejna M, Jaeger U, Chott A, Raderer M. Antibiotic treatment is not effective in patients infected with *Helicobacter pylori* suffering from extragastric MALT lymphoma. *J Clin Oncol*. 2006 Mar 20;24(9):1370-5. PubMed PMID: 16549831. IF=18,970
- 23: Grunberger B, Hauff W, Lukas J, **Wohrer S**, Zielinski CC, Streubel B, Chott A, Raderer M. 'Blind' antibiotic treatment targeting *Chlamydia* is not effective in patients with MALT lymphoma of the ocular adnexa. *Ann Oncol*. 2006 Mar;17(3):484-7. PubMed PMID: 16500916. IF=6,452
- 24: **Wohrer S**, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, Raderer M, Hoffmann M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. *Ann Oncol*. 2006 May;17(5):780-4. Epub 2006 Feb 23. PubMed PMID: 16497824. IF=6,452
- 25: **Woehrer S**, Hejna M, Skrabs C, Drach J, Zielinski CC, Jaeger U, Raderer M. Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. *Oncology*. 2005;69(6):499-502. Epub 2006 Jan 16. PubMed PMID: 16424679. IF=2,538
- 26: Raderer M, Streubel B, **Wohrer S**, Häfner M, Chott A. Successful antibiotic treatment of *Helicobacter pylori* negative gastric mucosa associated lymphoid tissue lymphomas. *Gut*. 2006 May;55(5):616-8. Epub 2005 Nov 18. PubMed PMID: 16299027; PubMed Central PMCID: PMC1856121. IF=10,614
- 27: Raderer M, **Wohrer S**, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B, Zielinski CC. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. *J Clin Oncol*. 2005 Nov 20;23(33):8442-6. PubMed PMID: 16293875. IF=18,970

- 28: Raderer M, Streubel B, **Wohrer S**, Chott A. Metachronous gastric MALT lymphoma and early gastric cancer. *Ann Oncol.* 2006 Apr;17(4):724. Epub 2005 Nov 9. PubMed PMID: 16282242. IF=6,452
- 29: **Wohrer S**, Bartsch R, Hejna M, Drach J, Raderer M. Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy. *Scand J Gastroenterol.* 2005 Oct;40(10):1222-5. PubMed PMID: 16265779. IF=1,966
- 30: Raderer M, Streubel B, **Wohrer S**, Puspöck A, Jaeger U, Formanek M, Chott A. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. *Clin Cancer Res.* 2005 May 1;11(9):3349-52. PubMed PMID: 15867234. IF=7,338
- 31: **Wohrer S**, Raderer M, Kaufmann H, Hejna M, Chott A, Zielinski CC, Drach J. Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. *Onkologie.* 2005 Feb;28(2):73-8. PubMed PMID: 15662110. IF=1,156
- 32: **Wohrer S**, Streubel B, Bartsch R, Chott A, Raderer M. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. *Clin Cancer Res.* 2004 Nov 1;10(21):7179-81. PubMed PMID: 15534090. IF=7,338
- 33: **Wohrer S**, Chott A, Drach J, Puspök A, Hejna M, Hoffmann M, Raderer M. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. *Ann Oncol.* 2004 Nov;15(11):1680-3. PubMed PMID: 15520071. IF=6,452
- 34: **Wohrer S**, Puspök A, Drach J, Hejna M, Chott A, Raderer M. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. *Ann Oncol.* 2004 Jul;15(7):1086-90. PubMed PMID: 15205203. IF=6,452
- 35: Kaufmann H, Raderer M, **Wohrer S**, Puspök A, Bankier A, Zielinski C, Chott A, Drach J. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. *Blood.* 2004 Oct 15;104(8):2269-71. Epub 2004 May 27. PubMed PMID: 15166030. IF=10,558

36: Rabitsch W, Prinz E, Ackermann J, **Wohrer S**, Kaufmann H, Seidl S, Keil F, Kalhs P, Greinix H, Gisslinger H, Leitner G, Drach J. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation. *Eur J Haematol.* 2004 Jan;72(1):26-31. PubMed PMID: 14962259. IF=2,785

37: Streubel B, Huber D, **Wohrer S**, Chott A, Raderer M. Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjögren's syndrome. *Clin Cancer Res.* 2004 Jan 15;10(2):476-80. PubMed PMID: 14760068. IF=7,338

38.: **Wohrer S**, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, Chott A, Raderer M. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). *Ann Oncol.* 2003 Dec;14(12):1758-61. PubMed PMID: 14630681. IF=6,452

Reviews, Case Reports & Letters:

1: Bojic M, Willinger B, Rath T, Tobudic S, Thalhammer F, Böhm A, Mitterbauer M, Schulenburg A, **Wöhrrer S**, Kalhs P, Rabitsch W. Fatal skin and pulmonary infection caused by *Hormographiella aspergillata* in a leukaemic patient: case report and literature overview. *Mycoses.* 2013 Nov;56(6):687-9. doi: 10.1111/myc.12087. Epub 2013 May 15. PubMed PMID: 23672484. IF=1,278

2: Valent P, Bonnet D, **Wöhrrer S**, Andreeff M, Copland M, Chomienne C, Eaves C. Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional, and Clinical Implications. *Cancer Res.* 2013 Feb 1;73(3):1037-1045. PMID: 23345162 IF=7,856

3: Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, **Wöhrrer S**, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C. Cancer stem cell definitions and terminology: the devil is in the details. *Nat Rev Cancer.* 2012 Nov;12(11):767-75. PMID: 23051844 IF=37,545

4: **Wohrer S**, Troch M, Raderer M. Therapy of gastric mucosa-associated lymphoid tissue lymphoma. *Expert Opin Pharmacother.* 2007 Jun;8(9):1263-73. Review. PubMed PMID: 17563261. IF=2,403

5: **Wohrer S**, Troch M, Raderer M. Treatment of localized primary gastric lymphoma. *J Clin Oncol*. 2006 Jun 10;24(17):2682; author reply 2682-3. PubMed PMID: 16763284. IF=18,970

6: Hejna M, **Wohrer S**, Schmidinger M, Raderer M. Postoperative chemotherapy for gastric cancer. *Oncologist*. 2006 Feb;11(2):136-45. Review. PubMed PMID: 16476834. IF=5,826

7: **Wohrer S**, Raderer M. Monoclonal gammopathy (MG) in extranodal marginal zone lymphoma (ENMZL). *Am J Hematol*. 2005 Dec;80(4):312. PubMed PMID: 16315250. IF=3,576

8: **Woehrer S**, Streubel B, Chott A, Hoffmann M, Raderer M. Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab. *Leuk Lymphoma*. 2005 Nov;46(11):1645-9. PubMed PMID: 16236618. IF=2,492

9: **Wohrer SS**, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. *Ann Oncol*. 2004 Nov;15(11):1585-95. Review. PubMed PMID: 15520058. IF=6,452

10: **Wohrer S**, Isaacson PG, Raderer M. Complete regression of primary gastric plasmacytoma following *Helicobacter pylori* eradication. *Ann Hematol*. 2004 Oct;83(10):666. Epub 2004 Jul 29. PubMed PMID: 15449033. IF=2,688

11: **Wohrer S**, Ackermann J, Baldia C, Seidl S, Raderer M, Simonitsch I, Drach J. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report. *Hematol J*. 2004;5(4):361-3. PubMed PMID: 15297854. IF=n.a.

12: **Wohrer S**, Raderer M, Streubel B, Chott A, Drach J. Concomitant occurrence of MALT lymphoma and multiple myeloma. *Ann Hematol*. 2004 Sep;83(9):600-3. Epub 2004 Apr 9. PubMed PMID: 15083336. IF=2,688

13: **Wohrer S**, Hejna M, Raderer M. *Helicobacter pylori* and pancreatic cancer. A working hypothesis from epidemiological studies. *JOP*. 2003 Jul;4(4):163-4; author reply 164. PubMed PMID: 12853685. IF=n.a.

Book Chapters:

1:Woehrer S, Miller CL, Eaves, CJ: Long-term Culture - Initiating Cell Assay for Mouse Cells.
Methods Mol Biol. 2013;946:257-66, Humana Press, PMID: 23179837